Maricel Apuli

CIK: 0002058197

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (47.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (11.8%)

Compensation grants

Other (G, F, J, C, D, …)7 (41.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BBIO

BridgeBio Pharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

BBIO
BridgeBio Pharma, Inc.
Oct 30, 2026
Sale(S)
Direct
2K shares at avg. $72.85$146K
BBIO
BridgeBio Pharma, Inc.
Aug 16, 2026
Tax Payment(F)
Direct
4.7K shares at avg. $79.86$376K
BBIO
BridgeBio Pharma, Inc.
Jul 30, 2026
Sale(S)
Direct
2K shares at avg. $80.06$160K
BBIO
BridgeBio Pharma, Inc.
May 16, 2026
Tax Payment(F)
Direct
4.7K shares at avg. $66.13$312K
BBIO
BridgeBio Pharma, Inc.
Apr 30, 2026
Sale(S)
Direct
2K shares at avg. $71.58$143K
BBIO
BridgeBio Pharma, Inc.
Mar 18, 2026
Award(A)
Direct
14.2K shares-
BBIO
BridgeBio Pharma, Inc.
Feb 26, 2026
Sale(S)
Direct
2K shares at avg. $66.00$132K
BBIO
BridgeBio Pharma, Inc.
Feb 17, 2026
Sale(S)
Direct
510 shares at avg. $74.31$38K
BBIO
BridgeBio Pharma, Inc.
Feb 16, 2026
Tax Payment(F)
Direct
4.3K shares at avg. $75.25$327K
BBIO
BridgeBio Pharma, Inc.
Dec 12, 2025
Tax Payment(F)
Direct
2K shares at avg. $75.15$151K
BBIO
BridgeBio Pharma, Inc.
Dec 8, 2025
Sale(S)
Direct
2K shares at avg. $74.26$149K
BBIO
BridgeBio Pharma, Inc.
Nov 16, 2025
Tax Payment(F)
Direct
4.8K shares at avg. $66.39$317K
BBIO
BridgeBio Pharma, Inc.
Aug 16, 2025
Tax Payment(F)
Direct
4.8K shares at avg. $51.32$245K
BBIO
BridgeBio Pharma, Inc.
Aug 7, 2025
Sale(S)
Direct
1K shares at avg. $45.44$45K
BBIO
BridgeBio Pharma, Inc.
May 16, 2025
Tax Payment(F)
Direct
4.8K shares at avg. $33.84$162K
BBIO
BridgeBio Pharma, Inc.
May 2, 2025
Sale(S)
Direct
1K shares at avg. $38.51$40K
BBIO
BridgeBio Pharma, Inc.
Mar 19, 2025
Award(A)
Direct
23.7K shares-

		Type	Shares	Price		Ownership
Oct 30, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	2,000	$72.85	$145,700	Direct
Aug 16, 2026	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	4,714	$79.86	$376,460	Direct
Jul 30, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	2,000	$80.06	$160,120	Direct
May 16, 2026	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	4,714	$66.13	$311,737	Direct
Apr 30, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	2,000	$71.58	$143,160	Direct
Mar 18, 2026	BBIO BridgeBio Pharma, Inc.	Award(A)	14,170	-	$0	Direct
Feb 26, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	2,000	$66.00	$132,000	Direct
Feb 17, 2026	BBIO BridgeBio Pharma, Inc.	Sale(S)	510	$74.31	$37,898	Direct
Feb 16, 2026	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	4,349	$75.25	$327,262	Direct
Dec 12, 2025	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	2,003	$75.15	$150,525	Direct
Dec 8, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	2,000	$74.26	$148,520	Direct
Nov 16, 2025	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	4,781	$66.39	$317,411	Direct
Aug 16, 2025	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	4,781	$51.32	$245,361	Direct
Aug 7, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	1,000	$45.44	$45,440	Direct
May 16, 2025	BBIO BridgeBio Pharma, Inc.	Tax Payment(F)	4,780	$33.84	$161,755	Direct
May 2, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	1,026	$38.51	$39,509	Direct
Mar 19, 2025	BBIO BridgeBio Pharma, Inc.	Award(A)	23,660	-	-	Direct

1-17 of 17 transactions

About Apuli Maricel

Apuli Maricel (SEC CIK 0002058197) files insider reports with the SEC as Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO).

Signal8 holds 17 ownership filings by Apuli Maricel (1 Form 3, 16 Form 4), filed between Feb 27, 2025 and Nov 3, 2026. Those filings report 17 transactions, from Mar 19, 2025 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Apuli Maricel's filings is in PALO ALTO, CA.

Recent filings by Apuli Maricel

Oct 30, 2026: Open-market sale of BBIO shares (Form 4, code S).
Aug 16, 2026: Tax withholding of BBIO shares (Form 4, code F).
Jul 30, 2026: Open-market sale of BBIO shares (Form 4, code S).
May 16, 2026: Tax withholding of BBIO shares (Form 4, code F).
Apr 30, 2026: Open-market sale of BBIO shares (Form 4, code S).

Other insiders filing for BridgeBio Pharma, Inc. (BBIO)

Kumar Neil, Chief Executive Officer
Trimarchi Thomas, President and CFO
Ellis Andrea, Director
Cook Jennifer E., Director
Valantine Hannah, Director
Lo Andrew, Director

How to read Form 4 transaction codes